Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
40 shown of 9,498 total abstracts
  1. Abstract 63652026-04-03 · 15:15 CT · S406
    Quality of life outcomes with Keytruda in patients with RCC
    J. Brahmer, R. Herbst, M. Krop · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 61262026-04-03 · 15:30 CT · Arie Crown Theater
    KEYNOTE-930: Keytruda (pembrolizumab) neoadjuvant in RCC
    R. Herbst, S. Peters, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 62512026-04-02 · 21:15 CT · S100A
    CheckMate-397: Opdivo (nivolumab) adjuvant in RCC
    S. Antonia, M. Krop, H. Rugo, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 65442026-04-05 · 19:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-755
    C. Saura, H. Borghaei, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 60942026-04-05 · 20:00 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in RCC
    J. Brahmer, S. Peters, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 65352026-04-03 · 13:00 CT · Hall B1
    KEYNOTE-920: Keytruda (pembrolizumab) neoadjuvant in RCC
    G. Curigliano, M. Krop, S. Peters, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 66492026-04-01 · 20:30 CT · E450
    CheckMate-596: Opdivo (nivolumab) maintenance in RCC
    E. Winer, G. Curigliano, S. Modi, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 65832026-04-02 · 15:00 CT · E450
    Quality of life outcomes with Opdivo in patients with RCC
    G. Curigliano, S. Peters, J. Cortes, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 65972026-04-04 · 14:15 CT · Hall B1
    KEYNOTE-812: Keytruda (pembrolizumab) neoadjuvant in RCC
    A. Spira, S. Tolaney, J. Cortes · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract 67172026-04-03 · 19:00 CT · Arie Crown Theater
    CheckMate-836: Opdivo (nivolumab) maintenance in RCC
    C. Robert, M.C. Garassino, T. Mok · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  11. Abstract 66172026-04-05 · 18:00 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in RCC
    J. Brahmer, H. Borghaei · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 64362026-04-03 · 15:45 CT · E450
    KEYNOTE-135: Keytruda (pembrolizumab) 2L in RCC
    C. Saura, S. Antonia, H. Borghaei, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 69332026-04-03 · 16:00 CT · E450
    KEYNOTE-243: Keytruda (pembrolizumab) neoadjuvant in RCC
    P. Schmid, M. Reck, M. Krop · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 64422026-04-02 · 14:00 CT · Hall B1
    CheckMate-213: Opdivo (nivolumab) neoadjuvant in RCC
    H. Borghaei, N. Rizvi, F. Andre, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  15. Abstract 61082026-04-02 · 18:30 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-766 study)
    C. Saura, S. Peters, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 65782026-04-02 · 19:30 CT · S406
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-109
    G. Curigliano, M. Krop, S. Modi · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 64052026-04-01 · 15:00 CT · S406
    CheckMate-201: Opdivo (nivolumab) maintenance in RCC
    S. Tolaney, G. Curigliano · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  18. Abstract 65472026-04-05 · 21:30 CT · Hall B1
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-488
    T. Mok, S. Tolaney · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 69942026-04-01 · 21:00 CT · S406
    CheckMate-536: Opdivo (nivolumab) neoadjuvant in RCC
    M. Reck, L. Paz-Ares, S. Tolaney, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract 60972026-04-05 · 21:30 CT · S100A
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-933
    R. Herbst, S. Antonia, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 66862026-04-05 · 13:45 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-100
    S. Tolaney, R. Herbst, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 66052026-04-04 · 14:15 CT · Hall B1
    KEYNOTE-742: Keytruda (pembrolizumab) neoadjuvant in RCC
    F. Andre, S. Antonia · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  23. Abstract 60242026-04-02 · 21:45 CT · Hall B1
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-527
    A. Spira, T. Mok, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  24. Abstract 62542026-04-03 · 13:30 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-948
    M. Reck, C. Saura, E. Winer, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  25. Abstract 69772026-04-01 · 14:15 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-385
    H. Borghaei, J. Brahmer, M. Reck · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  26. Abstract 68832026-04-02 · 14:45 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-603
    L. Paz-Ares, J. Brahmer, P. Schmid, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  27. Abstract 64912026-04-04 · 13:15 CT · Hall B1
    KEYNOTE-220: Keytruda (pembrolizumab) maintenance in RCC
    F. Andre, C. Robert, A. Spira, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  28. Abstract 68522026-04-03 · 14:00 CT · S100A
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-246
    T. Mok, P. Schmid · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  29. Abstract 65512026-04-05 · 15:30 CT · E450
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-668
    S. Antonia, S. Modi, C. Robert · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  30. Abstract 60962026-04-05 · 16:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-247
    A. Spira, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 62902026-04-05 · 20:00 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-681 study)
    A. Spira, G. Curigliano · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract 63742026-04-04 · 13:00 CT · E450
    KEYNOTE-791: Keytruda (pembrolizumab) 1L in RCC
    T. Mok, M.C. Garassino, P. Schmid, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 67042026-04-05 · 18:00 CT · E450
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-892
    L. Paz-Ares, P. Schmid, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 64282026-04-03 · 13:30 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-749
    T. Mok, M. Reck, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract 68472026-04-02 · 13:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-3
    S. Tolaney, G. Curigliano, H. Borghaei · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 66532026-04-02 · 14:15 CT · S406
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-434
    H. Rugo, N. Rizvi, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 60492026-04-03 · 19:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-565
    C. Robert, J. Brahmer · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  38. Abstract 68002026-04-04 · 19:45 CT · Hall B1
    CheckMate-752: Opdivo (nivolumab) adjuvant in RCC
    N. Rizvi, L. Paz-Ares, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  39. Abstract 63972026-04-05 · 18:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-518
    S. Antonia, A. Spira, S. Modi · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  40. Abstract 64402026-04-02 · 20:15 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-410
    C. Robert, S. Modi, S. Peters, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.